May 5, 2020. We are resuming work in a measured way, beginning with microinjections. Before we initiate or resume work on a project, we will contact clients to coordinate.
We are leaders in CRISPR/Cas9 gene targeting
. We have completed over 70 CRISPR/Cas9 projects including knockouts, reporter and point mutant knockins and targeted transgenics. more details
. Our fees
are low, our wait times
are short and our success rates
are high. New transgenic and targeted mice that we have created are featured in over 270 publications
since 2004. We are supported by the Case Western Reserve University School of Medicine
the Case Comprehensive Cancer Center
, the Clinical and Translational Science Collaborative
and by grants from the Cystic Fibrosis Foundation.